Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904144 | 0.83 | PGK1 (0.33) | PDE10A | |
| SCHEMBL28042369 | 0.77 | CDK1 (0.34) | CDK1CCNB1CCNE1CDK2CA2 | |
| SCHEMBL15904058 | 0.73 | PDE10A (0.36) | PDE10ACDK1CCNB1CCNE1CDK2 | |
| SCHEMBL2549958 | 0.69 | KMT2A (0.39) | — | |
| SCHEMBL30487819 | 0.69 | KMT2A (0.39) | — | |
| SCHEMBL15904125 | 0.66 | PDE10A (0.40) | PDE10A | |
| SCHEMBL15904001 | 0.62 | PDE10A (0.41) | PDE10A | |
| SCHEMBL27887711 | 0.60 | POLB (0.34) | — | |
| SCHEMBL13649005 | 0.59 | CDK1 (0.56) | PDE10ACDK1CCNB1CCNE1CDK2 | |
| SCHEMBL15904190 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447095-B2 | Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) | PALOBIOFARMA S.L. (ES) | 2016-09-20 | — | — | US | disclosed |
| EP-2948443-B1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA SL (ES) | 2016-08-31 | — | — | EP | disclosed |
| EP-2948443-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-12-02 | — | — | EP | disclosed |
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-11-26 | — | — | US | disclosed |
| WO-2014114695-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L (ES) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PDE12, PDE5A, PDE10A | PDE10A 3/4885CDK1 1162/4885CCNB1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.